Patients who undergo hepatic surgery for initially resectable liver metastases from colorectal cancer have a 70% risk of relapse. A recent phase III randomized trial has failed to demonstrate an improvement in disease-free survival with the addition of irinotecan to 5-fluorouracil and folinic acid as adjuvant treatment for patients with radically resected colorectal cancer with liver metastases.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Tomlinson, J. S. et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J. Clin. Oncol. 25, 4575–4580 (2007).
Nordlinger, B. et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 37 1, 1007–1016 (2008).
Fong, Y. et al. Liver resection for colorectal metastases. J. Clin. Oncol. 15, 938–946 (1997).
Kopetz, S. et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J. Clin. Oncol. 27, 3677–3683 (2009).
Ychou, M. et al. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann. Oncol. 20, 1964–1970 (2009).
Mitry, E. et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J. Clin. Oncol. 26, 4906–4911 (2008).
O'Connell, M. J. Oxaliplatin or irinotecan as adjuvant therapy for colon cancer: the results are in. J. Clin. Oncol. 27, 3082–3084 (2009).
Van Cutsem, E. et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J. Clin. Oncol. 27, 3117–3125 (2009).
Ychou, M. et al. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann. Oncol. 20, 674–680 (2009).
Saltz, L. B. et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J. Clin. Oncol. 2 5, 3456–3461 (2007).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Fotios Loupakis declares no competing interests. Alfredo Falcone declares associations with the following companies: Amgen, Merck and Roche (consultant, speaker's bureau, grant support) and Sanofi-Aventis (grant support).
Rights and permissions
About this article
Cite this article
Loupakis, F., Falcone, A. How useful is adjuvant irinotecan in stage IV CRC?. Nat Rev Clin Oncol 7, 190–191 (2010). https://doi.org/10.1038/nrclinonc.2010.32
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2010.32
